Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target

Cancer Gene Therapy

Volumn 7, Issue 9, 2000, Pages 1250-1256

  Arafat, Waleed ^a,b,c   Gómez Navarro, Jesús ^a,b   Xiang, Jialing ^a,b   Siegal, Gene P ^b,c   Alvarez, Ronald D ^a,b   Curiel, David T ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Cytotoxicity; erbB 2; Gene therapy; Single chain antibody

Indexed keywords

ANTIBODY; ERBB 2 ANTIBODY; SCFV ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; ONCOGENE NEU; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

EID: 0033779619     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700228     Document Type: Article

References (39)

1. Gene therapy for cancer
2. Inhibition of signaling from type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies
3. Reduction of erbB2 gene product in mammary carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides
4. Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation
5. Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation
6. Triplex formation inhibits HER-2/neu transcription in vitro
7. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells
8. Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector
9. Intracellular single-chain Fv antibodies: A knockout punch for neoplastic cells?
10. Intracellular antibodies as a new class of therapeutic molecules for gene therapy
11. Intracellular expression of single chain antibodies reverts ErbB-2 transformation
12. Intracellular expression of an antibody fragment-neutralizing p21(ras) promotes tumor regression
13. Ras and p53 intracellular targeting with recombinant single-chain Fv (scFv) fragments: A novel approach for cancer therapy?
14. Targeted tumor cytotoxicity mediated by intracellular single-chain anti-oncogene antibodies
15. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
16. erbB-2 Knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells
17. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective antiproliferative effect in erbB2 overexpressing cancer cell lines
18. Targeted tumor killing via an intracellular antibody against erbB-2
19. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody
20. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type1 gp120 single-chain antibody
21. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells
22. Functional knock-out of c-myb by an intracellular anti-c-Myb single-chain antibody
23. Phenotypic knock-out of the latent membrane protein 1 of Epstein-Barr virus by an intracellular single-chain antibody
24. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7
25. Intracellular expression of a single-chain antibody directed against human papillomavirus type 16 E7 oncoprotein achieves targeted antineoplastic effects
26. Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosen-sitivity
27. Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo
28. A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients
29. High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes
30. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy
31. Redox state of single chain Fv fragments targeted to the endoplasmic reticulum, cytosol, and mitochondria
32. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments
33. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies
34. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin
35. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection
36. Adenovirus enhancement of transferrin-polylysine-mediated gene delivery
37. The level of erbB2 expression predicts sensitivity to the cytotoxic effects of an intracellular anti-erbB2 sFv
38. Selection of antibodies for intracellular function using a two-hybrid in vivo system
39. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies